1-20 of 25
Barry Paul
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Barry Paul, Jirí Minarík, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Z Usmani, Lin Gu, Michelle Robeson, Michael Murphy, Camille Renard, Christine Chen, Luděk Pour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3383.
https://doi.org/10.1182/blood-2023-186997
Published: 2023
Journal Articles

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Jordan Snyder, Razan Mansour, Aytaj Mammadzadeh, Hamza Hashmi, Aimaz Afrough, Omar Alkharabsheh, Barry Paul, Shebli Atrash, Muhammad Umair Mushtaq, Barry S. Skikne, Nausheen Ahmed, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1985.
https://doi.org/10.1182/blood-2023-187487
Published: 2023
Journal Articles

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Hamid Ehsan, Myra Robinson, Patrick Meadors, Rushil Patel, Shanice Borden, Peter M. Voorhees, Delcan Walsh, Barry Paul, Manisha Bhutani, Cindy Varga, Shebli Atrash
Journal: Blood
Blood (2023) 142 (Supplement 1): 7416.
https://doi.org/10.1182/blood-2023-178114
Published: 2023
Journal Articles

Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Priyanka Venkatesh, Ghena Khasawneh, Hamza Hashmi, Omar Alkharabsheh, Barry Paul, Barry S. Skikne, Zahra Mahmoudjafari, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash
Journal: Blood
Blood (2023) 142 (Supplement 1): 1971.
https://doi.org/10.1182/blood-2023-188117
Published: 2023
Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani
Journal: Blood
Blood (2023) 142 (Supplement 1): 3380.
https://doi.org/10.1182/blood-2023-174972
Published: 2023
Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3386.
https://doi.org/10.1182/blood-2023-180761
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Who Received at Least 2 BCMA-Directed Therapies

Jordan Snyder, Zain Alsaddi, Omar Alkharabsheh, Barry Paul, Forat Lutfi, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Shebli Atrash
Journal: Blood
Blood (2023) 142 (Supplement 1): 1969.
https://doi.org/10.1182/blood-2023-185231
Published: 2023
Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2013.
https://doi.org/10.1182/blood-2023-181905
Published: 2023
Journal Articles

Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)

Cesar Rodriguez, Scott R. Solomon, Barry Paul, Omar Nadeem, Meenal Patel, Jian Wang, Rongda Xu, Melissa Junttila, Anneleen Daemen, Subhash Katewa, Pratik S Multani, Wilson I. Gonsalves
Journal: Blood
Blood (2023) 142 (Supplement 1): 4761.
https://doi.org/10.1182/blood-2023-173730
Published: 2023
Journal Articles

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Jonathan Lambird, John T Mckay, Meng-Yun Lin, Lindsey Abdelfattah, Manisha Bhutani, Barry Paul, Peter M. Voorhees, Cindy Varga, Shebli Atrash, David Duane Hurd
Journal: Blood
Blood (2023) 142 (Supplement 1): 6634.
https://doi.org/10.1182/blood-2023-180345
Published: 2023
Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Nicole Watts, Barry Paul, Saurabh Chhabra, Neha Korde, Xhevahire Begic, David M Foureau, David J. Chung, Mauricio Pineda-Roman, Brinda Koya, Cindy Varga, Jing Ai, Natonya Daniels, Sarah Norek, Sara A Sutton, Michelle B Anderson, Ashley N Jewell, Paul W Eldridge, Donna Acampora, James T Symanowski, Luciano J. Costa, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4393–4395.
https://doi.org/10.1182/blood-2022-160071
Published: 2022
Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4440–4441.
https://doi.org/10.1182/blood-2022-160204
Published: 2022
Journal Articles

Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Polina Bellman, Wei Cui, Zahra Mahmoudjafari, Shebli Atrash, Barry Paul, Hamza Hashmi, Rajesh Banderudrappagari, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed
Journal: Blood
Blood (2022) 140 (Supplement 1): 8074–8075.
https://doi.org/10.1182/blood-2022-168450
Published: 2022
Journal Articles

Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Evguenia Ouchveridze, Chandandeep Singh, Shebli Atrash, Barry Paul, Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi
Journal: Blood
Blood (2022) 140 (Supplement 1): 7164–7165.
https://doi.org/10.1182/blood-2022-168368
Published: 2022
Journal Articles

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2739.
https://doi.org/10.1182/blood-2021-148508
Published: 2021
Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2021-145903
Published: 2021
Journal Articles

Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

David M Foureau, Manisha Bhutani, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Reed Friend, Barry Paul, Myra M Robinson, James T Symanowski, Lawrence J Druhan, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 1585.
https://doi.org/10.1182/blood-2021-152505
Published: 2021
Journal Articles

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Barry Paul, MDMS, Myra Robinson, MSPH, Kristen Cassetta, Daniel Slaughter, Jordan Robinson, Ami P Ndiaye, NP, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA, Shebli Atrash, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-141637
Published: 2020
Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-138485
Published: 2020
Journal Articles

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Barry Paul, MDMS, James Symanowski, PhD, Paul Osipoff, Sarah Norek, BSN, RN, Ami P Ndiaye, NP, Jordan Robinson, Shebli Atrash, MD, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-141623
Published: 2020